Figure 1.
Selection of patients with cancer for retrospective assessment of bilirubin and anthracycline-induced LV systolic dysfunction. Data from 751 participants were analyzed after excluding 654 patients with cancer because they did not have a post-anthracycline LV systolic function assessment and 51 patients with cancer for total bilirubin >2 mg/dl.